EUVIMEDEUVIMED entdecken
Open Access

Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches

Anna-Maria Hoffmann-Vold iD, Elizabeth R Volkmann iD

Journal of Scleroderma and Related Disorders · 2021-02 · 6 (1) · 37-43

DOI: 10.1177/2397198319891282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Scleroderma and Related Disorders, online erschienen am 20.12.2019. Verfasst von Anna-Maria Hoffmann-Vold und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The majority of research studies in systemic sclerosis focus largely on addressing skin and cardiopulmonary manifestations. Fewer studies assess the pathogenesis and treatment of gastrointestinal tract involvement in systemic sclerosis, despite the fact that the majority of patients with systemic sclerosis have gastrointestinal manifestations and these manifestations are a leading cause of death in systemic sclerosis. The present review provides a comprehensive update on morbidity and mortality outcomes related to gastrointestinal involvement in systemic sclerosis. This review also describes conventional and emerging approaches to managing gastrointestinal symptoms in systemic sclerosis. Recent developments in systemic sclerosis–gastrointestinal research efforts have revealed promising treatment targets, including specific auto-antibodies and microbiota alterations. This review will conclude with an overview of future research directions that may improve our understanding of systemic sclerosis–gastrointestinal involvement and ultimately help to alleviate suffering from this devastating dimension of systemic sclerosis.

Schlagwörter

Stichwörter der Autor:innen

Systemic sclerosisgastrointestinalmicrobiotamotilityscleroderma

Autor:innen und Institutionen

  • Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Division of Rheumatology, Department of Medicine, University of California-Los Angeles (UCLA), Los Angeles, CA, USA.

ORCID-Profile: Anna-Maria Hoffmann-Vold, Elizabeth R Volkmann

Zitieren

APA

Hoffmann-Vold, A. M., & Volkmann, E. R. (2021). Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. Journal of Scleroderma and Related Disorders, 6(1), 37-43. https://doi.org/10.1177/2397198319891282

Vancouver

Hoffmann-Vold AM, Volkmann ER. Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches. Journal of Scleroderma and Related Disorders. 2021;6(1):37-43. doi:10.1177/2397198319891282

BibTeX
@article{HoffmannVold2021,
  author = {Hoffmann-Vold, Anna-Maria and Volkmann, Elizabeth R},
  title = {Gastrointestinal involvement in systemic sclerosis: Effects on morbidity and mortality and new therapeutic approaches},
  journal = {Journal of Scleroderma and Related Disorders},
  year = {2021},
  volume = {6},
  number = {1},
  pages = {37--43},
  doi = {10.1177/2397198319891282}
}
Kostenlos starten →